Stock events for Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals closed an underwritten public offering of common shares, generating gross proceeds of approximately $747.5 million. Terns reported positive Phase 1 CARDINAL data for TERN-701, which led to a significant surge in the stock price. Terns discontinued its oral GLP-1 receptor agonist program (TERN-601). The company granted equity inducement awards to new employees. Leerink Partners initiated coverage with an Outperform rating and a $58 price target. The stock has seen substantial gains, with a 569.31% increase between January 8, 2025, and January 7, 2026, and a 1,142.48% increase between March 3, 2025, and February 27, 2026.
Demand Seasonality affecting Terns Pharmaceuticals, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Terns Pharmaceuticals, Inc. does not currently have commercialized products or services, and therefore, traditional "demand seasonality" for its products and services is not applicable. There is some historical seasonality observed in the company's stock performance, with February showing the highest probability of positive returns and January the lowest.
Overview of Terns Pharmaceuticals, Inc.’s business
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases, primarily in oncology and obesity. Its pipeline includes TERN-701 for Chronic Myeloid Leukemia, TERN-501 for metabolic dysfunction-associated steatohepatitis (MASH), and the TERN-800 series for obesity. The company is strategically pivoting to focus on oncology by the end of 2025, with its future largely dependent on the success of TERN-701.
TERN’s Geographic footprint
Terns Pharmaceuticals, Inc. is headquartered in Foster City, California, United States. The company's operational footprint is primarily in the U.S., with a shareholder base concentrated in the United States (86.0%), and smaller percentages in the United Kingdom, Canada, and Switzerland.
TERN Corporate Image Assessment
Terns Pharmaceuticals' brand reputation appears to be largely positive, driven by the promising clinical data for TERN-701. The company has a consensus "Buy" rating from analysts. The discontinuation of the TERN-601 obesity program had a limited impact on the company's reputation, as the positive developments with TERN-701 overshadowed it.
Ownership
Terns Pharmaceuticals, Inc. is overwhelmingly controlled by institutional investors. As of February 27, 2026, Terns Pharmaceuticals had 290 institutional owners and shareholders holding a total of 120,237,799 shares. Major institutional owners include BlackRock, Inc., Morgan Stanley, Adage Capital Partners Gp, L.l.c., Vanguard Group Inc, Vivo Capital, LLC, Soleus Capital Management, L.P., Orbimed Advisors Llc, Deep Track Capital, LP, Commodore Capital Lp and Candriam Luxembourg S.C.A. Individual ownership accounts for a small percentage (0.95%) of the company.
